Gilead's Kite Pauses CAR-T Work After Severe Neurotoxicity In A Small Number Of Patients

Kite's Cindy Perettie said there were no patient deaths, and that Gilead's FDA decision on anito-cel is due December 23.

Share
Gilead's Kite Pauses CAR-T Work After Severe Neurotoxicity In A Small Number Of Patients

Gilead's cell-therapy unit Kite has put a program on a partial clinical hold after seeing severe neurotoxicity in a small number of patients, Kite Executive Vice President Cindy Perettie said on Gilead's third-quarter earnings call Thursday. She stressed there were "no patient deaths."

A pause to investigate

Asked by a Leerink Partners analyst about the partial hold on the Palisades 1 and 2 trials, Perettie said the program uses rapid manufacturing, a three-day process. Kite decided to pause and investigate differences it saw in grade 3 and grade 4 ICANN events in a small number of patients before moving forward.

She said there were no deaths and no grade 5 events, and that Kite would keep investors informed as it learns more. Perettie contrasted Gilead's three-day process with the one-day manufacturing used by two other companies in the space.

Kite's autoimmune program, KITE-363, does not use rapid manufacturing, she said, so its rheumatology and neurology Phase 1 trials continue.

A monthly HIV pill also on hold

A second hold came up in HIV. Chief Medical Officer Dietmar Berger told a UBS analyst that candidate 3107, a monthly oral treatment, is on clinical hold because some prodrug compounds produce metabolites with an unexpected impact. Gilead is working through the hold and developing backup molecules in parallel, he said.

Gilead, which develops medicines for HIV, viral hepatitis, COVID-19 and cancer, has a market value of $197.4 billion as of Thursday's report.

A strong quarter around the holds

The call otherwise carried strong numbers. Base business sales rose 16% from a year earlier to $8.2 billion, which CEO Daniel O'Day called Gilead's strongest growth in more than a decade. HIV sales rose 18%, and Trodelvy sales rose 42%.

Chief Commercial Officer Johanna Mercier said Gilead is preparing for the December 23 FDA decision date on anito-cel in fourth-line-plus relapsed or refractory multiple myeloma. It is targeting activation of 80% of its authorized treatment centers within six months of launch.

The FDA decision on anito-cel is due December 23, and Perettie has promised more information on the paused trials as it arrives.

Sources

More on Gilead Sciences

All Gilead Sciences (GILD) coverage →